Heparin-induced thrombocytopenia epidemiology and demographics

Revision as of 16:58, 20 December 2011 by Vanbot (talk | contribs) (Protected "Heparin-induced thrombocytopenia epidemiology and demographics": Robot: Protecting all pages from category Drugs ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
Jump to navigation Jump to search

Heparin-induced thrombocytopenia

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Heparin-induced thrombocytopenia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Heparin-induced thrombocytopenia epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Heparin-induced thrombocytopenia epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Heparin-induced thrombocytopenia epidemiology and demographics

CDC on Heparin-induced thrombocytopenia epidemiology and demographics

Heparin-induced thrombocytopenia epidemiology and demographics in the news

Blogs on Heparin-induced thrombocytopenia epidemiology and demographics

Directions to Hospitals Treating Heparin-induced thrombocytopenia

Risk calculators and risk factors for Heparin-induced thrombocytopenia epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]

Overview

Heparin-induced thrombocytopenia is diagnosed when the platelet count falls by > 50% typically after 5-10 days of heparin therapy. It has been found to occur with increased frequencies in females, white population and patients over age of 60 years. An episode of Heparin-induced thrombocytopenia increases risks for other future thrombo-embolic events.

Epidemiology and demographics

Mortality

  • Heparin-induced thrombocytopenia is diagnosed when the platelet count falls by > 50% typically after 5-10 days of heparin therapy. The affected individuals have an increased risks of having another thromboembolic event (20-50% increased risks)
  • Mortality rate can be as high as 20%
  • 1 in 10 patients suffer from other morbidities (amputations or other arterial venous or both thrombo-embolic events)

United States of America

  • Incidence varies from 1-5%.

Race

Some studies have shown that the incidences of heparin-induced thrombocytopenia (HIT) are commoner among white patients compared to non-white patients.

Sex

Female have increased risks compared to male for heparin-induced thrombocytopenia

Age

Risks for development of HIT Increases with age (>60years)

Reference